Leora R Feldstein, Amadea Britton, Lauren Grant, Ryan Wiegand, Jasmine Ruffin, Tara M Babu, Melissa Briggs Hagen, Jefferey L Burgess, Alberto J Caban-Martinez, Helen Y Chu, Katherine D Ellingson, Janet A Englund, Kurt T Hegmann, Zuha Jeddy, Adam S Lauring, Karen Lutrick, Emily T Martin, Clare Mathenge, Jennifer Meece, Claire M Midgley, Arnold S Monto, Gabriella Newes-Adeyi, Leah Odame-Bamfo, Lauren E W Olsho, Andrew L Phillips, Ramona P Rai, Sharon Saydah, Ning Smith, Laura Steinhardt, Harmony Tyner, Meredith Vandermeer, Molly Vaughan, Sarang K Yoon, Manjusha Gaglani, Allison L Naleway
IMPORTANCE: Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited. OBJECTIVE: To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents. DESIGN, SETTING, AND PARTICIPANTS: Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years...
February 6, 2024: JAMA